{"nctId":"NCT00714233","briefTitle":"Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)","startDateStruct":{"date":"2002-08"},"conditions":["Polycystic Ovary Syndrome"],"count":43,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Oral Contraceptive Pills (Yasmin)"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Behavioral: Lifestyle Modification"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Metformin","otherNames":[]},{"name":"Oral Contraceptive Pills (Yasmin)","otherNames":["Yasmin oral COntraceptive tabs"]},{"name":"Lifestyle Modification","otherNames":[]},{"name":"placebo","otherNames":["pharmacy matched placebo capsules"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Menstrual irregularity defined as cycle length \\> 45 days\n* Overweight as BMI \\> 25\n* Clinical evidence of hirsuitism or acne\n* Testosterone \\> 50ng/dL\n\nExclusion Criteria:\n\n* History of diabetes mellitus\n* History of Cushing's disease\n* History of hyperprolactinemia\n* Untreated hypo or hyperthyroidism\n* History of adrenal hyperplasia\n* Significant renal impairment\n* Received oral contraceptives, estrogen or progestin or other drugs known to effect lipoprotein metabolism within 2 months of starting the study\n* Exercise \\> 10 hours per week","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"12 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Measure Number of Adolescent Girls With PCOS Who Can be Successfully Recruited Into a Randomized Clinical Trial That Includes Lifestyle Modification","description":"The measure is to determine a number of successfully recruited overweight or obese adolescents to a randomized trial of lifestyle therapy in the community of Rochester, NY","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Weight Loss in Lifestyle Intervention Group","description":"In the adolescent women assigned to the lifestyle program, did the intervention program obtain weight reduction as measured by change in BMI","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"6.6"}]}]}]},{"type":"SECONDARY","title":"Change in Free Androgen Index (FAI)","description":"Secondary measures of reduction in androgen measures of the different treatment arms. This is a ratio of total testosterone to sex hormone binding globulin (SHBG). The lower values correlate with lower amount of free testosterone. FAI \\<4 is consistent with a normal range.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"3.2"},{"groupId":"OG001","value":"-16.7","spread":"8"},{"groupId":"OG002","value":"-13.7","spread":"10.9"},{"groupId":"OG003","value":"1.2","spread":"12.3"}]}]}]},{"type":"SECONDARY","title":"Change in SHBG","description":"Measurement of SHBG by treatment group pre and post intervention","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"8.6"},{"groupId":"OG001","value":"77","spread":"38.4"},{"groupId":"OG002","value":"17.6","spread":"18.3"},{"groupId":"OG003","value":"2","spread":"8.4"}]}]}]},{"type":"SECONDARY","title":"Triglyceride Concentration by Treatment Group","description":"Change in triglyceride measures pre and post intervention as representative of lipid changes by treatment group; metformin, lifestyle intervention, oral contraceptive or placebo","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.3","spread":"24.1"},{"groupId":"OG001","value":"4.6","spread":"41"},{"groupId":"OG002","value":"2.2","spread":"36.4"},{"groupId":"OG003","value":"-6.6","spread":"27.8"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Glucose","description":"Change in fasting glucose concentration by treatment group pre to post intervention","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"10.3"},{"groupId":"OG001","value":"6.9","spread":"8.7"},{"groupId":"OG002","value":"0.4","spread":"7.2"},{"groupId":"OG003","value":"-1.1","spread":"7.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}}